

# Michele Senni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/240386/publications.pdf>

Version: 2024-02-01

171  
papers

21,309  
citations

34076

52  
h-index

10724

138  
g-index

184  
all docs

184  
docs citations

184  
times ranked

14819  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemodynamic arterial changes in heart failure: a proposed new paradigm of "heart and vessels failure". <i>Minerva Cardiology and Angiology</i> , 2022, 70, .	0.4	8
2	<scp>Angiotensinâ€“neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14
3	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
4	Prevalence, Characteristics, and Outcomes of COVID-19â€“Associated Acute Myocarditis. <i>Circulation</i> , 2022, 145, 1123-1139.	1.6	118
5	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. <i>European Journal of Internal Medicine</i> , 2022, 102, 8-16.	1.0	10
6	Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. <i>Heart Failure Reviews</i> , 2022, , .	1.7	5
7	Four aces of heart failure therapy: systematic review of established and emerging therapies for heart failure with reduced ejection fraction. <i>Cardiology Plus</i> , 2022, 7, 20-28.	0.2	1
8	Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 937-945.	0.8	8
9	Renin profiling predicts neurohormonal response to sacubitril/valsartan. <i>ESC Heart Failure</i> , 2021, 8, 719-724.	1.4	3
10	Rationale for and Practical Use of Sacubitril/Valsartan in the Patientâ€™s Journey with Heart Failure and Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2021, 7, e06.	1.2	1
11	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 89-97.	1.6	12
12	Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19. <i>Atherosclerosis</i> , 2021, 328, 136-143.	0.4	25
13	A 57-year-old man with rapidly progressive pulmonary hypertension. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	2
14	Sacubitrilâ€“valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
15	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
16	Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	0.7	8
17	Integrating High-Sensitivity Troponin T andâ€“Sacubitril/Valsartan Treatment inâ€“HFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	1.9	21
18	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1919.	3.8	72

#	ARTICLE	IF	CITATIONS
19	Usefulness of regional right ventricular and right atrial strain for prediction of early and late right ventricular failure following a left ventricular assist device implant: A machine learning approach. <i>International Journal of Artificial Organs</i> , 2020, 43, 297-314.	0.7	16
20	Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed ( de novo ) heart failure: a subgroup analysis of the TRANSITION study. <i>European Journal of Heart Failure</i> , 2020, 22, 303-312.	2.9	52
21	Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 1405-1411.	0.5	3
22	Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2326-2329.	0.8	1
23	Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction. <i>European Heart Journal Supplements</i> , 2020, 22, L124-L128.	0.0	6
24	NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 822-833.	1.9	21
25	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
26	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
27	Incremental prognostic value of echocardiography of left ventricular remodeling and diastolic function in STICH trial. <i>Cardiovascular Ultrasound</i> , 2020, 18, 17.	0.5	5
28	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , 2020, 22, 1065-1075.	2.9	31
29	Beneficial effects of adaptive servo-ventilation on natriuretic peptides and diastolic function in acute heart failure patients with preserved ejection fraction and sleep-disordered breathing. <i>Sleep and Breathing</i> , 2019, 23, 287-291.	0.9	11
30	Do Existing Definitions Identify Subgroup Phenotypes or Reflect the Natural History of Heart Failure With Preserved Ejection Fraction?. <i>Circulation</i> , 2019, 140, 366-369.	1.6	24
31	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1426-1433.	2.9	27
32	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
33	Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations. <i>Cardiac Failure Review</i> , 2019, 5, 78-82.	1.2	3
34	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013441.	1.6	62
35	Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. <i>European Journal of Heart Failure</i> , 2019, 21, 998-1007.	2.9	233
36	Monitoring of biomarkers in heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M5-M8.	0.0	16

#	ARTICLE	IF	CITATIONS
37	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.9	65
38	Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. International Journal of Cardiology, 2019, 281, 158-165.	0.8	26
39	Heart failure with preserved ejection fraction in Asia: the far side of the moon?. European Journal of Heart Failure, 2019, 21, 37-39.	2.9	6
40	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarctionâ€”Results of the CHIARA MIA 1 Trial. Clinical Pharmacology in Drug Development, 2019, 8, 942-951.	0.8	17
41	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498.	1.9	272
42	Transvenous pacing in pediatric patients with bipolar lumenless lead: Ten-year clinical experience. International Journal of Cardiology, 2018, 255, 45-49.	0.8	8
43	Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. International Journal of Cardiology, 2018, 253, 97-104.	0.8	34
44	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. International Journal of Cardiology, 2018, 266, 187-192.	0.8	27
45	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. European Journal of Preventive Cardiology, 2018, 25, 889-895.	0.8	12
46	Lessons learned in acute heart failure. European Journal of Heart Failure, 2018, 20, 630-641.	2.9	33
47	Preâ€discharge and early postâ€discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 281-291.	2.9	33
48	Rationale and design of <scp>TRANSITION</scp>: a randomized trial of preâ€discharge vs. postâ€discharge initiation of sacubitril/valsartan. ESC Heart Failure, 2018, 5, 327-336.	1.4	42
49	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. European Journal of Heart Failure, 2018, 20, 514-522.	2.9	35
50	Impact of systolic blood pressure on the safety and tolerability of initiating and upâ€titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. European Journal of Heart Failure, 2018, 20, 491-500.	2.9	59
51	Sacubitril/valsartan: from a large clinical trial to clinical practice. Journal of Cardiovascular Medicine, 2018, 19, 473-479.	0.6	8
52	Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in highâ€risk populations? Insights from the DAVIDâ€Berg study. European Journal of Heart Failure, 2018, 20, 1540-1548.	2.9	11
53	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis. Circulation, 2018, 138, 1088-1099.	1.6	253
54	Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. International Journal of Cardiology, 2018, 264, 118-123.	0.8	27

#	ARTICLE	IF	CITATIONS
55	Exercise Hemodynamic and Functional Capacity After Mitral Valve Replacement in Patients With Ischemic Mitral Regurgitation. <i>Circulation: Heart Failure</i> , 2018, 11, e004056.	1.6	13
56	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). <i>ESC Heart Failure</i> , 2018, 5, 830-841.	1.4	29
57	Dose-dependent efficacy of $\beta$ -blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 273, 141-146.	0.8	13
58	Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. <i>European Journal of Heart Failure</i> , 2018, 20, 1257-1266.	2.9	130
59	Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. <i>International Journal of Cardiology</i> , 2017, 226, 132-135.	0.8	7
60	Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. <i>International Journal of Cardiology</i> , 2017, 226, 136-140.	0.8	10
61	Clinical correlates of autonomic response during tilting test in hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 255-261.	0.6	0
62	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	178
63	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	1.2	193
64	Aspirin Desensitization in Patients With Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	43
65	Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 197-202.	1.3	17
66	High-Sensitive Cardiac Troponin for Prediction of Clinical Heart Failure. <i>Circulation</i> , 2017, 135, 1506-1508.	1.6	14
67	Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. <i>European Journal of Heart Failure</i> , 2017, 19, 710-717.	2.9	116
68	Prognostic scores: one fits all?. <i>European Journal of Heart Failure</i> , 2017, 19, 588-588.	2.9	0
69	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 768-776.	0.8	11
70	Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies. <i>European Journal of Heart Failure</i> , 2017, 19, 926-946.	2.9	188
71	Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. <i>European Journal of Heart Failure</i> , 2017, 19, 1551-1553.	2.9	10
72	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. <i>International Journal of Cardiology</i> , 2017, 248, 414-420.	0.8	4

#	ARTICLE	IF	CITATIONS
73	External closed-circuit cooling system for management of patients after device implantation: A feasibility study. <i>International Journal of Cardiology</i> , 2017, 241, 235-237.	0.8	1
74	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 995.	3.0	164
75	Global Longitudinal Strain in master athletes and in hypertensive patients with the same degree of septal thickness. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2017, 27, 1411-1416.	1.3	4
76	Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 102-112.	6.1	18
77	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 440-451.	1.0	38
78	Echocardiographic Outflow Pump Ramp Test in Centrifugal-Flow Left Ventricular Assist Device. <i>International Journal of Artificial Organs</i> , 2017, 40, 128-131.	0.7	3
79	Atrial fibrillation, cognitive impairment, frailty and disability in older heart failure patients. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 616-623.	0.6	20
80	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	1.0	114
81	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2016, 18, 185-191.	2.9	13
82	Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 79-108.	0.9	7
83	Reasons why patients suffering from chronic heart failure at very low risk for mortality die. <i>International Journal of Cardiology</i> , 2016, 223, 947-952.	0.8	2
84	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 320-328.	0.4	26
85	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016, 18, 54-65.	2.9	73
86	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>European Journal of Heart Failure</i> , 2016, 18, 1193-1202.	2.9	180
87	Is 3D Echo With Ramp Test Indicated in Detecting Blood Flow Obstructions in HeartWare LVAD?. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2126-2127.	1.2	0
88	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	46
89	Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients. <i>Vascular Pharmacology</i> , 2016, 80, 85-90.	1.0	18
90	Incremental Value of Gait Speed in Predicting Prognosis of Older Adults With Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 289-298.	1.9	93

#	ARTICLE	IF	CITATIONS
91	Sacubitril/valsartan (LCZ696) for the treatment of heart failure. Expert Review of Cardiovascular Therapy, 2016, 14, 145-153.	0.6	18
92	Haemodynamics of Heart Failure With Preserved Ejection Fraction: A Clinical Perspective. Cardiac Failure Review, 2016, 2, 102-105.	1.2	12
93	The Pilot European Survey of Atrial Fibrillation: how to look at heart failure through a keyhole. European Journal of Heart Failure, 2015, 17, 541-543.	2.9	1
94	Comparison of the Baseline Demographics of the LCZ696 PARADIGM-HF and TITRATION Studies. Journal of Cardiac Failure, 2015, 21, S45.	0.7	1
95	The 30â€day metric in acute heart failure revisited: data from <scp>INâ€HF</scp> Outcome, an Italian nationwide cardiology registry. European Journal of Heart Failure, 2015, 17, 1032-1041.	2.9	32
96	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. European Journal of Heart Failure, 2015, 17, 760-763.	2.9	16
97	Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery. Thrombosis and Haemostasis, 2015, 114, 423-431.	1.8	26
98	Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Thrombosis and Haemostasis, 2015, 113, 272-282.	1.8	46
99	Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. European Journal of Heart Failure, 2015, 17, 1231-1239.	2.9	85
100	Low Incidence of Gastrointestinal Bleeding and Pump Thrombosis in Patients Receiving the INCOR LVAD System in the Long-term Follow-up. International Journal of Artificial Organs, 2015, 38, 542-547.	0.7	14
101	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 2015, 36, 1106-1114.	1.0	53
102	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2015, 115, 790-796.	0.7	37
103	Determinants of functional capacity after mitral valve annuloplasty or replacement for ischemic mitral regurgitation. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 1595-1603.	0.4	16
104	An Intriguing Case Report of Functional Mitral Regurgitation Treated With MitraClip. Medicine (United States), 2015, 94, e608.	0.4	3
105	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. European Journal of Heart Failure, 2015, 17, 1066-1074.	2.9	85
106	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
107	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. JACC: Heart Failure, 2015, 3, 136-145.	1.9	265
108	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439.	1.0	80

#	ARTICLE	IF	CITATIONS
109	Cardiogenic shock: How to overcome a clinical dilemma. Unmet needs in Emergency medicine. International Journal of Cardiology, 2015, 186, 19-21.	0.8	4
110	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. Expert Review of Cardiovascular Therapy, 2015, 13, 799-809.	0.6	10
111	Prognostic scores in heart failure " Critical appraisal and practical use. International Journal of Cardiology, 2015, 188, 1-9.	0.8	45
112	Genetic Variants Are Not Associated with Outcome in Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) Trials. Cardiology, 2015, 130, 69-81.	0.6	4
113	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC: Heart Failure, 2015, 3, 487-496.	1.9	204
114	A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2015, 85, E129-39.	0.7	6
115	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. Journal of the American College of Cardiology, 2015, 66, 2059-2071.	1.2	118
116	Cavotricuspid Isthmus Ablation and Subcutaneous Monitoring Device Implantation in a 2-Year-Old Baby with 2 SCN5A Mutations, Sinus Node Dysfunction, Atrial Flutter Recurrences, and Drug Induced Long-QT Syndrome: A Tricky Case of Pediatric Overlap Syndrome?. Journal of Cardiovascular Electrophysiology, 2015, 26, 346-349.	0.8	3
117	Transaortic Chordal Cutting. Journal of the American College of Cardiology, 2015, 66, 1687-1696.	1.2	141
118	Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. International Journal of Cardiology, 2015, 199, 319-325.	0.8	39
119	Successful treatment of subacute constrictive pericarditis with interleukin-1 <sup>2</sup> receptor antagonist (anakinra). Clinical and Experimental Rheumatology, 2015, 33, 294-5.	0.4	12
120	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 2014, 35, 3442-3451.	1.0	78
121	Transcatheter treatment of chronic mitral regurgitation with the MitraClip system. Journal of Cardiovascular Medicine, 2014, 15, 173-188.	0.6	9
122	Novel approaches to the post-myocardial infarction/heart failure neural remodeling. Heart Failure Reviews, 2014, 19, 611-619.	1.7	15
123	Restrictive mitral valve annuloplasty versus mitral valve replacement for functional ischemic mitral regurgitation: An exercise echocardiographic study. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 447-453.e2.	0.4	26
124	Developing Therapies for Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	1.9	267
125	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq1 1 0784314 18BT /Over	0.7	14
126	Reasons why patients suffering from chronic heart failure at very high risk for death survive. International Journal of Cardiology, 2014, 177, 213-218.	0.8	3



#	ARTICLE	IF	CITATIONS
127	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	1.0	304
128	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	0.7	8
129	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs.) <i>Tj ETQq1 1 0.784314 rgBT /Ov</i> <i>Cardiology</i> , 2014, 173, 163-169.	0.8	98
130	Treatment with inotropes and related prognosis in acute heart failure: Contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1056-1065.	0.3	23
131	How should I treat a challenging case of MitraClip implantation?. <i>EuroIntervention</i> , 2014, 10, 887-890.	1.4	0
132	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. <i>International Journal of Cardiology</i> , 2013, 168, 3691-3697.	0.8	20
133	Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. <i>European Journal of Heart Failure</i> , 2013, 15, 1220-1227.	2.9	28
134	Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score. <i>International Journal of Cardiology</i> , 2013, 163, 206-211.	0.8	108
135	Natriuretic peptides and the Framingham Risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study. <i>International Journal of Cardiology</i> , 2013, 168, 5093-5095.	0.8	7
136	Ranolazine in Heart Failure With Preserved Left Ventricular Ejection Fraction and Microvascular Dysfunction: Case Report and Literature Review. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 665-669.	1.0	4
137	Multicenter Prospective Observational Study on Acute and Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 473-481.	1.6	170
138	Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (REDâ€œHF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
139	A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2012, 33, 2080-2087.	1.0	88
140	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012, 33, 1750-1757.	1.0	652
141	Use of implantable cardioverter defibrillator and cardiac resynchronization therapy. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 675-683.	0.6	5
142	Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysisâ€œ. <i>European Journal of Heart Failure</i> , 2012, 14, 1139-1146.	2.9	100
143	Acute heart failure patient profiles, management and inâ€œhospital outcome: results of the Italian Registry on Heart Failure Outcome. <i>European Journal of Heart Failure</i> , 2012, 14, 1208-1217.	2.9	112
144	Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial. <i>Circulation</i> , 2012, 125, 2639-2648.	1.6	210

#	ARTICLE	IF	CITATIONS
145	Analysis of Circumferential and Longitudinal Left Ventricular Systolic Function in Patients With Non-Ischemic Chronic Heart Failure and Preserved Ejection Fraction (from the CARRY-IN-HFpEF Study). <i>American Journal of Cardiology</i> , 2012, 109, 383-389.	0.7	34
146	Cardiac Resynchronization In combination with BEta blocker treatment in advanced chronic Heart Failure (CARIBE-HF): the results of the CARIBE-HF study. <i>Acta Cardiologica</i> , 2011, 66, 573-580.	0.3	9
147	Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2010, 5, 196-207.	1.5	18
148	Bacterial Pericarditis due to <i>Providencia stuartii</i> . <i>Circulation</i> , 2010, 122, e401-3.	1.6	17
149	Toward the development of a fully elastic mitral ring: Preliminary, acute, in vivo evaluation of biomechanical behavior. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 174-179.	0.4	6
150	Implantation of an Elastic Ring at Equator of the Left Ventricle Influences Cardiac Mechanics in Experimental Acute Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1791-1798.	1.2	6
151	The Titan can help titin: from micro to macro myocardial elasticity. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 153-158.	0.6	3
152	A Novel Prognostic Index to Determine the Impact of Cardiac Conditions and Co-Morbidities on One-Year Outcome in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2006, 98, 1076-1082.	0.7	52
153	Surgical ventricular reverse remodeling in severe ischemic dilated cardiomyopathy: The relevance of the left ventricular equator as a prognostic factor. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 131, 357-363.e1.	0.4	21
154	End-systolic pressure/volume relationship during dobutamine stress echo: a prognostically useful non-invasive index of left ventricular contractility. <i>European Heart Journal</i> , 2005, 26, 2404-2412.	1.0	64
155	Temporal Trends in Survival and Hospitalizations in Outpatients With Chronic Systolic Heart Failure in 1995 and 1999. <i>Journal of Cardiac Failure</i> , 2005, 11, 270-278.	0.7	38
156	Left main stem patch plasty and aortic root homograft in Takayasu's disease. <i>Annals of Thoracic Surgery</i> , 2004, 77, 314-317.	0.7	9
157	Diastolic heart failure in the community: Clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. <i>Journal of Cardiac Failure</i> , 2002, 8, 279-287.	0.7	134
158	Aortic valve disease with severe ventricular dysfunction: stentless valve for better recovery. <i>Annals of Thoracic Surgery</i> , 2002, 74, 2016-2021.	0.7	17
159	Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: Data from a large nationwide cardiology database (IN-CHF Registry). <i>American Heart Journal</i> , 2002, 143, 45-55.	1.2	162
160	Heart failure with preserved systolic function. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1277-1282.	1.2	247
161	How patients with heart failure are managed in Italy. <i>European Journal of Heart Failure</i> , 2001, 3, 257-260.	2.9	12
162	Congestive Heart Failure in the Community. <i>Archives of Internal Medicine</i> , 1999, 159, 29.	4.3	335

#	ARTICLE	IF	CITATIONS
163	Use of echocardiography in the management of congestive heart failure in the community. Journal of the American College of Cardiology, 1999, 33, 164-170.	1.2	140
164	Left ventricular systolic and diastolic function after pericardiectomy in patients with constrictive pericarditis. Journal of the American College of Cardiology, 1999, 33, 1182-1188.	1.2	89
165	Fibrinogen is an Independent Marker for Thoracic Aortic Atherosclerosis. American Journal of Cardiology, 1998, 81, 321-326.	0.7	64
166	Congestive Heart Failure in the Community. Circulation, 1998, 98, 2282-2289.	1.6	925
167	Congestive Heart Failure in Elderly Patients. Mayo Clinic Proceedings, 1997, 72, 453-460.	1.4	50
168	Multiplane transoesophageal echocardiographic detection of thoracic aortic plaque is a marker for coronary artery disease in women. International Journal of Cardiology, 1997, 61, 269-275.	0.8	7
169	The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels. Clinical Cardiology, 1997, 20, 767-772.	0.7	19
170	Medical treatment of end-stage heart failure. Cardiovascular Drugs and Therapy, 1996, 10, 617-622.	1.3	2
171	Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. Cardiac Failure Review, 0, 8, .	1.2	2